Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.61 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.59 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.56 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.56 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | ASAH2 | Q9NR71 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.53 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1456458 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL19557778 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456455 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL20143550 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL4023787 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL1456463 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL277126 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| Hexadecanoic Acid Isopropylamide SCHEMBL1457147 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL12459875 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 | |
| SCHEMBL5005939 | 1.00 | FAAH (1.00) | FAAHMEN1KMT2AMAPK1DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10385024-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20150299131-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC (US) | 2015-10-22 | — | — | US | disclosed |
| US-7989422-B2 | Antibacterial agents | ALCHEMIA LIMITED (AU) | 2011-08-02 | — | — | US | disclosed |
| US-20090023669-A1 | Antibacterial Agents | ALCHEMIA LIMITED (AU) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299131-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP2 | FAAH 949/4885MEN1 4780/4885KMT2A 3985/4885 |
| US-10385024-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP2 | FAAH 949/4885MEN1 4780/4885KMT2A 3985/4885 |
| US-20090023669-A1 | Antibacterial Agents | MRPL21, FUT6, FUT5 | FAAH 3749/4885MEN1 2906/4885KMT2A 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.